Award
National Cancer Institute 5R01CA270147-04
Engineering the Next Generation of Safer Hsp90 Inhibitors
Recipient
University of Notre Dame
Award Amount
$453,812.00
Ceiling
$453,812.00
Awarded
January 12, 2026
Identifier
5R01CA270147-04
A grant awarded to the University of Notre Dame to develop safer Hsp90 inhibitors for cancer treatment by optimizing C-terminal domain inhibitors and advancing them towards clinical trials.
Description
This project aims to optimize and evaluate C-terminal inhibitors of Hsp90 for cancer treatment, specifically targeting head and neck squamous cell carcinoma (HNSCC), with the goal of delivering a new Investigational New Drug (IND) for clinical evaluation. The inhibitors target the Hsp90 C-terminal domain to avoid the dose-escalating toxicities seen with N-terminal domain inhibitors.